Valo Therapeutics has announced a collaboration with global contract research organization, Texcell, to investigate immune responses to PeptiCRAd-1 in its Phase 1 clinical study.
ValoTx’s PeptiCRAd-1 combines the power of a tumor-specific adenovirus (expressing immune-stimulatory molecules CD40L and OX40L) with immunogenic tumor peptides derived from NY-ESO-1 and MAGE-A3 proteins thereby generating tumor-specific, cytotoxic T-cells that will attack and kill cancer cells.
“We are delighted to establish this collaboration with Texcell. The study is a great opportunity to maximize the anti-tumor potential of our oncolytic adenovirus VALO-D102 by directing the immune responses towards tumor specific antigens, driving enhanced tumor-specific T-cell responses in cancer patients. This collaboration should give us valuable information about the immunological mechanism of action of PeptiCRAd-1, as we reinvent immunotherapy to make it more powerful,” says Sari Pesonen, CSO at ValoTx.
About the study
The previously announced Germany based open-label, non-randomized, multi-center study of up to 15 patients will explore the safety and immunological mechanism of action of PeptiCRAd-1 plus checkpoint inhibitor (CPI) pembrolizumab in multiple cancer types, as well as to obtain early information on the clinical activity of this combination therapy. The collaboration with Texcell will provide insights on PeptiCRAd-1’s ability to modulate immune responses and the mechanism of action of VALO-D102.